Nykode Therapeutics : Q1 2024 Financial Results – presentation

Q1 2024

Results Presentation

May 14, 2024

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

2

Today's presenters from Nykode management

International management team with solid drug development experience

MICHAEL ENGSIG	AGNETE FREDRIKSEN	HARALD GURVIN	KLAUS EDVARDSEN
Chief Executive Officer	Chief Scientific Officer &	Chief Financial Officer	Chief Research &
	Business Development		Development Officer

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

3

Q1 2024 Highlights

• Presented top line conclusions from the updated analysis from the Phase 2 VB-C-02 trial in advanced cervical cancer, affirming prolonged benefits and indicating a synergistic treatment effect of VB10.16 and atezolizumab (Tecentriq®).
• Announced advances in the inverse vaccine platform, showing promising results in treating autoimmune diseases and underscoring the platform's potential.
• Presented additional preclinical data on the inverse vaccine platform, demonstrating long-term protection against diabetes following treatment withdrawal.

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

4

Post-period end Highlights

• Initiated Phase 2 VB-C-04 trial in second line HPV16-positive cervical cancer in patients with HPV16-positive,PD-L1-positive, recurrent, or metastatic cervical cancer.
• Concluded enrollment of the 6 mg cohort in the VB-C-03 (VB10.16) trial in first-line head and neck cancer patients.
• Presented new preclinical data from our collaboration with Genentech, focusing on the differentiation of our proprietary vaccine technology.
• Announced clinical collaboration with MSD to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positivehigh-risk locally advanced cervical cancer

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

5

Broad pipeline targeting early to late-stage cancer treatment

									Upcoming
	Asset	Indication	Rights		Preclinical	Phase 1	Phase 2	Phase 3	Catalyst
Oncology
		HPV16+ cervical cancer		1				C-02,C-04	Finalize enrolment Pt 1
							(Q4 2024)
		HPV16+ head and neck cancer		2					Dose level
	VB10.16					C-03		recommendation
									(H2 2024)
Off-the-shelf		HPV16+ locally advanced		2
						C-05	Protocol in development
		cervical cancer
	Regeneron	Undisclosed		3					Selection of lead
	programs							candidate
	NYK011	Colorectal: pre-cancerous							Update
	polyps to cancer							(H2 2024)
		Melanoma, lung, bladder, renal,		4
Individua-		head and neck cancer; locally						N-01
	advanced and metastatic tumors
lized	VB10.NEO
		Incurable locally advanced and		4			N-02
		metastatic tumors
Infectious Disease			3
Regeneron programs	Undisclosed
Autoimmune
Internal		Undisclosed							Update
							(H1 2024)

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

6

R&D update

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

7

VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in ≥2L r/m cervical cancer

CPI Monotherapy in r/m CC

VB10.16 plus
atezolizumab	Atezolizumab in
in PD-L1+
PD-L1+†††
(analysis from April 2023*)

Pembrolizumab

in PD-L1+**

Cemiplimab in	Tisotumab vedotin
PD-L1+††	(PD-L1 agnostic) ‡ ‡

Trial name	C-02		Skyscraper-04,	Keynote-158	Empower-Cervical 1,		InnovaTV 301,
	atezolizumab arm	cemiplimab arm		tisotumab vedotin arm
ORR	29%		16%	17%	18%		18%
mPFS	6.3 mo		1.9 mo	2.1 mo	3.0 mo		4.2 mo
mOS	Not reached		10.6 mo	11.0 mo	13.9 mo		11.5 mo
(25.0+ mo)

*Updated analysis (March 2024) closely mirrors previously reported positive outcome.

Notes: The data shown on this slide represents third-party clinical trials involving different trial designs and patient populations. These trials are not head-to-head evaluations of VB10.16 against standard of care

• Salani et al. Efficacy and safety results from Skyscraper-04: An open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer. IGCS 2023. ** Chung et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019
  †† Tewari et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022

‡ ‡ Confirmatory phase 3 RCT evaluating tisotumab vedotin vs. investigator's choice chemotherapy (topotecane, vinorelbine, gemcitabine, irinotecan, or pemetrexed). Ignace Vergote: innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator's Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer. ESMO 2023.

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

8

Maximizing addressable patient populations by diversifying offerings and broadening therapeutic scope

Building a cancer vaccine franchise following strong clinical validation

Validation Today

Future Opportunities

Adjuvant Settings

C-05

2L Cervical Cancer	C-04

C-02 data validates

opportunity and

creates fast to market

opportunity

C-02

2L Cervical Cancer

Fast to market

strategy

Indication Expansions C-03

Expansion into other

solid tumor types, including head and neck cancer, in front- line settings

1L SCCHN

Expand indications and into front-line settings

Move earlier to expand patient population and explore long-term efficacy with RFS

Adjuvant Cervical,

SCCHN

Anal, vulvar,	PD-L1 negative
vaginal, penile	patients

Expand to target the broad

addressable patient population

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

9

VB10.NEO Individualized cancer immunotherapy

Nykode Therapeutics | Q1 '24 webcast | Non-confidential

10